These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 14713717)

  • 21. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy.
    Chambers CA; Kuhns MS; Egen JG; Allison JP
    Annu Rev Immunol; 2001; 19():565-94. PubMed ID: 11244047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural analysis of CTLA-4 function in vivo.
    Masteller EL; Chuang E; Mullen AC; Reiner SL; Thompson CB
    J Immunol; 2000 May; 164(10):5319-27. PubMed ID: 10799894
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CTLA-4 negative signaling via lipid rafts: A new perspective.
    Rudd CE; Martin M; Schneider H
    Sci STKE; 2002 Apr; 2002(128):pe18. PubMed ID: 11972356
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses.
    Khattri R; Auger JA; Griffin MD; Sharpe AH; Bluestone JA
    J Immunol; 1999 May; 162(10):5784-91. PubMed ID: 10229811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PD-1 deficiency results in the development of fatal myocarditis in MRL mice.
    Wang J; Okazaki IM; Yoshida T; Chikuma S; Kato Y; Nakaki F; Hiai H; Honjo T; Okazaki T
    Int Immunol; 2010 Jun; 22(6):443-52. PubMed ID: 20410257
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CTLA-4 differentially regulates T cell responses to endogenous tissue protein versus exogenous immunogen.
    Walker LS; Ausubel LJ; Chodos A; Bekarian N; Abbas AK
    J Immunol; 2002 Dec; 169(11):6202-9. PubMed ID: 12444125
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytotoxic T-lymphocyte antigen-4 and programmed death-1 function as negative regulators of lymphocyte activation.
    Carter LL; Carreno BM
    Immunol Res; 2003; 28(1):49-59. PubMed ID: 12947224
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells.
    Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Sharpe AH; Vallera DA
    J Immunol; 1999 Jun; 162(11):6368-77. PubMed ID: 10352249
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TCR subunit specificity of CTLA-4-mediated signaling.
    Siu E; Carreno BM; Madrenas J
    J Leukoc Biol; 2003 Dec; 74(6):1102-7. PubMed ID: 12972512
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CTLA-4 regulates tolerance induction and T cell differentiation in vivo.
    Walunas TL; Bluestone JA
    J Immunol; 1998 Apr; 160(8):3855-60. PubMed ID: 9558090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD28/CTLA-4/B7 costimulatory pathway blockade affects regulatory T-cell function in autoimmunity.
    Vogel I; Kasran A; Cremer J; Kim YJ; Boon L; Van Gool SW; Ceuppens JL
    Eur J Immunol; 2015 Jun; 45(6):1832-41. PubMed ID: 25727069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytotoxic T lymphocyte antigen 4 (CD152) regulates self-reactive T cells in BALB/c but not in the autoimmune NOD mouse.
    Piganelli JD; Poulin M; Martin T; Allison JP; Haskins K
    J Autoimmun; 2000 Mar; 14(2):123-31. PubMed ID: 10677243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A molecular perspective of CTLA-4 function.
    Teft WA; Kirchhof MG; Madrenas J
    Annu Rev Immunol; 2006; 24():65-97. PubMed ID: 16551244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential role of CTLA-4 in regulation of resting memory versus naive CD4 T cell activation.
    Metz DP; Farber DL; Taylor T; Bottomly K
    J Immunol; 1998 Dec; 161(11):5855-61. PubMed ID: 9834064
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The inhibitory effects of transforming growth factor-beta-1 (TGF-beta1) in autoimmune diseases.
    Prud'homme GJ; Piccirillo CA
    J Autoimmun; 2000 Feb; 14(1):23-42. PubMed ID: 10648114
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human CTLA-4 is expressed in situ on T lymphocytes in germinal centers, in cutaneous graft-versus-host disease, and in Hodgkin's disease.
    Vandenborre K; Delabie J; Boogaerts MA; De Vos R; Lorré K; De Wolf-Peeters C; Vandenberghe P
    Am J Pathol; 1998 Apr; 152(4):963-73. PubMed ID: 9546357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation.
    Cross AH; Girard TJ; Giacoletto KS; Evans RJ; Keeling RM; Lin RF; Trotter JL; Karr RW
    J Clin Invest; 1995 Jun; 95(6):2783-9. PubMed ID: 7539461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exocytosis of CTLA-4 is dependent on phospholipase D and ADP ribosylation factor-1 and stimulated during activation of regulatory T cells.
    Mead KI; Zheng Y; Manzotti CN; Perry LC; Liu MK; Burke F; Powner DJ; Wakelam MJ; Sansom DM
    J Immunol; 2005 Apr; 174(8):4803-11. PubMed ID: 15814706
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Viewpoint: therapeutic implications of CTLA-4 compartmentalization.
    Baroja ML; Madrenas J
    Am J Transplant; 2003 Aug; 3(8):919-26. PubMed ID: 12859525
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lessons from CTLA-4 deficiency and checkpoint inhibition.
    Lo B; Abdel-Motal UM
    Curr Opin Immunol; 2017 Dec; 49():14-19. PubMed ID: 28806575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.